Atrium Therapeutics, Inc. Common Stock (RNA) is a publicly traded Healthcare sector company. As of May 21, 2026, RNA trades at $13.12 with a market cap of $221.52M and a P/E ratio of -2.56. RNA moved -1.81% today. Year to date, RNA is -82.36%; over the trailing twelve months it is -57.91%. Its 52-week range spans $11.95 to $73.06. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces RNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes RNA SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $13.12 |
| Market Cap | $221.52M |
| P/E Ratio | -2.56 |
| EPS | $-4.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.06 |
| 52-Week Low | $11.95 |
| Volume | 148.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $18.75M |
| Net Income | $-684.63M |
| Gross Margin | 0.00% |
2 analysts cover RNA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.